May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Retinal Function Following Transpupillary Thermotherapy for Occult Choroidal Neovascularization in Age–Related Macular Degeneration: A Short–Term Study by Focal ERGs
Author Affiliations & Notes
  • E. Pirozzi
    Ophthalmology, Catholic University, Rome, Italy
  • F. Coccimiglio
    Ophthalmology, Catholic University, Rome, Italy
  • C. Manganelli
    Ophthalmology, Catholic University, Rome, Italy
  • G. Iarossi
    Ophthalmology, Catholic University, Rome, Italy
  • A. Minnella
    Ophthalmology, Catholic University, Rome, Italy
  • A. Fadda
    Tecnologie e Salute, Istituto Superiore di Sanita', Rome, Italy
  • F. Focosi
    Ophthalmology, Catholic University, Rome, Italy
  • B. Falsini
    Ophthalmology, Catholic University, Rome, Italy
  • Footnotes
    Commercial Relationships  E. Pirozzi, None; F. Coccimiglio, None; C. Manganelli, None; G. Iarossi, None; A. Minnella, None; A. Fadda, None; F. Focosi, None; B. Falsini, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 5128. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Pirozzi, F. Coccimiglio, C. Manganelli, G. Iarossi, A. Minnella, A. Fadda, F. Focosi, B. Falsini; Retinal Function Following Transpupillary Thermotherapy for Occult Choroidal Neovascularization in Age–Related Macular Degeneration: A Short–Term Study by Focal ERGs . Invest. Ophthalmol. Vis. Sci. 2004;45(13):5128.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To evaluate focal electroretinograms (FERGs) in patients with occult subfoveal choroidal neovascularization (CNV) due to age–related macular degeneration (AMD) before and after transpupillary thermotherapy (TTT), in order to analyze the short–term effects of this subthreshold treatment on macular function. Methods:Fourteen patients (14 eyes) with occult subfoveal CNV due to AMD (average pre–treatment visual acuity: 20/150, range: 20/400–20/60), undergoing TTT delivered using an infrared (810 nm) diode laser (spot size 3.0 mm, laser power 350 to 800 mW, duration 60 sec.), were evaluated immediately before (baseline) and one and six weeks after treatment by FERGs, Snellen visual acuity testing and fluorescein angiography (FA). For the FERG recordings, a 630–nm photocoagulator aiming beam was modified for use as a 41–Hz square–wave stimulus, which was presented to the macular region, under direct visualization, on a light–adapting background using a Goldmann–type lens (visual angle, 18 deg; mean luminance, 50 cd/m2). FERG and clinical data were analyzed in a blind fashion.Results:Six weeks after TTT, four patients had significant FERG amplitude increase and phase advance (> 2 SD from the baseline test–retest variability). None had significant amplitude decrease or phase delay. Visual acuity increased of two or more lines from baseline in four patients and was stable in the remaining patients. Six out of 14 patients had a decrease in exudation at FA, while none had an increase from baseline. Improvement in FERG parameters after TTT was always associated with improvement in visual acuity (two lines) and decrease in exudation. Post–TTT FERG amplitude increase was greatest in patients with worse baseline acuity (Pearson’s r= –0.6, p < 0.05). Conclusions:The results indicate that, in a short–term follow–up, TTT for occult subfoveal CNV due to AMD does not result in a decline of retinal function, which may even be improved in some patients with specific baseline characteristics (worse baseline acuity). FERG amplitude and phase changes after TTT may predict a favorable outcome of both lesion characteristics and visual acuity.

Keywords: age–related macular degeneration • electroretinography: clinical • laser 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×